Therapeutic Effect of Mirogabalin on Peripheral Neuropathic Pain due to Lumbar Spine Disease

Study Design: Retrospective study. Purpose: This study aims to evaluate the effectiveness of mirogabalin in treatment of peripheral neuropathic pain due to lumbar spine disease. Overview of Literature: Mirogabalin is a novel selective ligand for the α2δ subunit of voltage-gated Ca channels. Methods:...

Full description

Saved in:
Bibliographic Details
Published in:Asian spine journal 2021, 15(3), , pp.349-356
Main Authors: Kim, Kyongsong, Isu, Toyohiko, Kokubo, Rinko, Iwamoto, Naotaka, Morimoto, Daijiro, Kawauchi, Masaaki, Morita, Akio
Format: Article
Language:English
Subjects:
Age
Back pain
Calcium channels (voltage-gated)
Clinical outcomes
Clinical Study
Drug dosages
Gender differences
Hospitals
Leg
leg symptom
Low back pain
lumbar spine disease
Magnetic resonance imaging
mirogabalin
neuralgia
Patients
Peripheral neuropathy
Quality of life
Sleep
Spine (lumbar)
Standard deviation
Statistical analysis
Surgery
정형외과학
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Study Design: Retrospective study. Purpose: This study aims to evaluate the effectiveness of mirogabalin in treatment of peripheral neuropathic pain due to lumbar spine disease. Overview of Literature: Mirogabalin is a novel selective ligand for the α2δ subunit of voltage-gated Ca channels. Methods: Between April and December 2019, we used mirogabalin to treat 60 consecutive patients (mean age, 67.6 years) with leg symptoms due to lumbar disease. The treatment outcome after 8 weeks of mirogabalin therapy was evaluated by comparing the preand post-administration Numerical Rating Scale (NRS) for leg symptoms and sleep disturbance, the NRS and Roland–Morris Disability Questionnaire for low back pain (LBP), and the quality of life (QOL) score (based on EuroQol five-dimension five-level scale). Results: Mirogabalin treatment was stopped at less than eight weeks in eight patients. The remaining 52 patients for evaluation were divided as group 1 (17 patients who presented with leg symptoms that lasted for less than 3 months) and group 2 (35 patients with leg symptoms that lasted longer than 3 months). The leg symptoms and LBP in both groups significantly improved at 4 and 8 weeks of treatment, and sleep disturbance and QOL were improved at 8 weeks as well. Compared to group 2, the pretreatment leg symptoms and QOL were significantly worse in group 1, and their improvement after 8 weeks of mirogabalin treatment was significantly better (p
ISSN:1976-1902
1976-7846
DOI:10.31616/asj.2020.0136